Pharmaceuticals

Acute Intermittent Porphyria Market Forecast Highlighting Key Trends And Expansion Potential

April 28, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Is The Market Size Of The Acute Intermittent Porphyria Market Expected To Scale Between 2026 And 2030?

The market for acute intermittent porphyria has experienced robust expansion over recent years. Projections indicate a rise from $4.66 billion in 2025 to reach $4.97 billion by 2026, demonstrating a compound annual growth rate (CAGR) of 6.5%. Historically, this expansion has been driven by factors such as the limited access to diagnostic facilities for AIP, insufficient awareness regarding acute intermittent porphyria, a continued reliance on conventional treatment approaches, the expansion of hospital and clinic infrastructure, and an increasing need for genetic testing.

The acute intermittent porphyria market is projected for substantial expansion in the coming years. This market is anticipated to reach $6.33 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.2%. Factors contributing to this growth during the forecast period include the introduction of new therapies and hematin formulations, broader availability of DNA and enzyme testing services, greater adoption of telemedicine for rare diseases, intensified awareness and educational initiatives for medical professionals, and the implementation of advanced monitoring and digital health solutions. Key trends expected within this period encompass wider acceptance of genetic and enzyme-based diagnostic methods, heightened understanding regarding the early detection and management of AIP, an increase in prophylactic hematin infusions and targeted treatments, the proliferation of specialized treatment facilities and research endeavors, and the seamless incorporation of telemedicine and remote patient monitoring specifically for AIP patients.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19264&type=smp

What Major Factors Are Driving The Acute Intermittent Porphyria Market Forward?

An anticipated increase in the occurrence of metabolic disorders is projected to drive the expansion of the acute intermittent porphyria market in the future. These conditions represent a collection of ailments resulting from atypical chemical processes within the body, which interfere with normal metabolic functions. The widespread incidence of metabolic disorders can be attributed to inherited traits, lifestyle choices, environmental impacts, and enhanced detection and recognition. The growing occurrence of metabolic disorders is prompting the pharmaceutical sector to allocate resources towards developing therapies for uncommon and inherited conditions like acute intermittent porphyria. For instance, in December 2023, according to Cleveland Clinic, a US-based nonprofit academic medical center, inherited metabolic disorders collectively impact approximately 1 in 1,000 to 2,500 births worldwide. Consequently, the widespread presence of metabolic disorders is fueling the expansion of the acute intermittent porphyria market.

How Is The Acute Intermittent Porphyria Market Categorized Across Its Segment Groups?

The acute intermittent porphyria market covered in this report is segmented –

1) By Diagnosis: Urine Test, Blood Test, Serum Test, DNA Test, Other Diagnosis

2) By Treatment: Prophylactic Hematin Infusions, Gonadotropin-Releasing Hormone Analogues, Other Treatments

3) By End-Users: Hospitals And Clinics, Ambulatory Surgical Centers, Research Centers

Subsegments:

1) By Urine Test: Urine Porphobilinogen (PBG) Test, Urine Aminolevulinic Acid (ALA) Test, Urine Color Change Test

2) By Blood Test: Plasma Porphyrin Levels Test, Blood Aminolevulinic Acid (ALA) Test, Complete Blood Count (CBC) Test

3) By Serum Test: Serum Porphyrin Levels Test, Liver Function Test (LFT), Serum ALA and PBG Enzyme Test

4) By DNA Test: Genetic Mutation Testing, Gene Sequencing Test

5) By Other Diagnosis: Stool Test for Porphyrins, Imaging Tests (CT/MRI Scans for Complications), Enzyme Activity Assays.

Which Trends Are Impacting The Progress Of The Acute Intermittent Porphyria Market?

Companies operating in the acute intermittent porphyria market are concentrating on developing advanced products, such as acute intermittent porphyria management tablets, to better serve customers with improved functionalities. Acute intermittent porphyria management tablets are defined as oral medications utilized to manage or prevent the symptoms and acute attacks associated with AIP. For instance, in October 2023, Alembic Pharmaceuticals Ltd., an India-based pharmaceutical company, announced the US Food & Drug Administration (USFDA) approval for its Chlorpromazine Hydrochloride Tablets USP, 10 mg, 25 mg, 50 mg, 100 mg, and 200 mg. These Chlorpromazine hydrochloride tablets USP, available in doses of 10 mg, 25 mg, 50 mg, 100 mg, and 200 mg, are used for managing symptoms of psychotic disorders and treating schizophrenia. They also assist in controlling nausea and vomiting, reducing restlessness and apprehension before surgical procedures, and act as an adjunct in treating tetanus. Furthermore, these tablets are applied in the management of acute intermittent porphyria, to control manic symptoms of manic-depressive illness, and to provide relief from intractable hiccups.

Which Firms Are Influencing Competition In The Acute Intermittent Porphyria Market?

Major companies operating in the acute intermittent porphyria market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Sanofi SA, AstraZeneca Plc, Novartis AG, GlaxoSmithKline Plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Novo Nordisk A/S, Regeneron Pharmaceuticals Inc., Daiichi Sankyo Company Limited, Vertex Pharmaceuticals Inc., Eisai Co. Ltd., Octapharma AG, BioMarin Pharmaceutical Inc., Swedish Orphan Biovitrum AB, Alnylam Pharmaceuticals Inc., Mylan N.V., Clinuvel Pharmaceuticals Ltd., Recordati Rare Diseases Inc.

Get The Full Acute Intermittent Porphyria Market Report:

https://www.thebusinessresearchcompany.com/report/acute-intermittent-porphyria-global-market-report

Which Region Represents The Largest Share Of The Acute Intermittent Porphyria Market?

North America was the largest region in the acute intermittent porphyria market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the acute intermittent porphyria market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Acute Intermittent Porphyria Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/acute-intermittent-porphyria-global-market-report

Browse Through More Reports Similar to the Global Acute Intermittent Porphyria Market 2026, By The Business Research Company

Acute Myeloid Leukemia Market Report 2026

https://www.thebusinessresearchcompany.com/report/acute-myeloid-leukemia-global-market-report

Acute Ischemic Stroke Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/acute-ischemic-stroke-drugs-global-market-report

Post Acute Care Market Report 2026

https://www.thebusinessresearchcompany.com/report/post-acute-care-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795